We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Q2 Solutions, Illumina Collaborate
News

Q2 Solutions, Illumina Collaborate

Q2 Solutions, Illumina Collaborate
News

Q2 Solutions, Illumina Collaborate

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Q2 Solutions, Illumina Collaborate"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Q2 Solutions has announced the expansion of its genomic companion diagnostics (CDx) capabilities. This comes as a result of an agreement between Q2 Solutions – EA Genomics and Illumina, a global leader in genomics, to establish a framework for developing next-generation sequencing-based (NGS) CDx assays.

The expansion of Q2 Solutions’ CDx development portfolio will further enhance the company’s wide range of end-to-end services that extend from biomarker discovery and development to the application of precision medicine through its clinical trials laboratory network. Under the terms of the agreement, Q2 Solutions will develop NGS assays using the Illumina MiSeqDx® instrument. The MiSeqDx is the first NGS instrument to be cleared by the U.S. Food and Drug Administration (FDA) for in vitro diagnostic purposes in clinical laboratories.

This alliance brings together two industry-leading companies, combining Q2 Solutions’ global experience and local knowledge, as well as its deep genomic, scientific and medical expertise, with Illumina’s ability to apply innovative technologies to the analysis of genetic variation and function. “At Q2 Solutions, we partner with our customers to bring innovative solutions to meet the needs of patients across the world,” said Costa Panagos, chief executive officer, Q2 Solutions.

“The industry is quickly moving toward a world of precision medicine, and we believe companion diagnostics are key to unlocking a new future for patients who are battling diseases, such as cancer, where more targeted and accurate therapies are critical. Q2 Solutions helped develop 62 percent of all FDA-approved precision medicine drugs of 2015, and we look forward to the opportunity to continue working with our customers on an approach that can help improve healthcare globally.”

Advertisement